LARIMAR THERAPEUTICS INC (LRMR)
Health Care · Rare disease / orphan drug biotechnology · NASDAQ
A clinical-stage biotech pioneering cell-penetrating peptide technology to deliver essential proteins to mitochondria in rare genetic diseases, with nomlabofusp targeting Friedreich's ataxia.
What LARIMAR THERAPEUTICS INC does
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases using its proprietary cell penetrating peptide (CPP) technology platform. The company's lead candidate, nomlabofusp, is designed to deliver frataxin protein to mitochondria in patients with Friedreich's ataxia (FA), a rare, progressive, fatal genetic disease characterized by insufficient frataxin levels. Nomlabofusp represents the first potential therapy intended to systemically increase FXN levels in FA patients, and the platform has potential applications in other rare and orphan diseases with intracellular deficiencies.
Themes: ["Rare disease therapeutics","Orphan drugs / Friedreich's ataxia","Mitochondrial protein delivery","Cell penetrating peptides"]
Fundamentals
- Price$4.13 as of 2026-07-09 close
- Market cap$433M as of 2026-07-10
- 1-year return+19.4% as of 2026-07-09 close
- ROE-134.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.78 as of 2026-07-10
Key risks (from latest filing)
["Anaphylaxis and serious adverse events identified in ongoing clinical studies; two participants experienced serious adverse events including anaphylaxis and seizure requiring withdrawal from the study","Clinical development stage with no approved products; success depends on completing multiple ongoing clinical trials and obtaining regulatory approval, with uncertain timelines and outcomes","Limited cash runway; company anticipates current cash and recent equity financing will fund operations only into Q2 2027, requiring additional capital raises or partnership agreements"]
Competitors & peers
- Reata Pharmaceuticals
- Sesen Bio
- Translate Bio
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.